BSEBeryl Drugs LtdMediumNeutral
Announced Fri, 20 Mar · 17:51 IST

Beryl Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/04/2026 ,inter alia, to consider and approve 1. To consider and approve the ....

Director Flagged GovernanceManagement Changes View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-1.9%1-day move
₹21.40
prior close
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-1.9-5.1-14.0-9.9-11.3-11.9+19.0+5.7-11.2+3.6
Up moveDown movePending
AI summary

Beryl Drugs Ltd has called a board meeting on April 1, 2026. The main agenda is to fix the date and notice for an Extra Ordinary General Meeting (EOGM) to regularize the appointment of Mr. Shailendra Pathak as Whole Time Director, appoint Mrs. Neha Sarda as an Independent Director, and approve a material Related Party Transaction with Aminova Infusions P. Ltd, where Mr. Pathak holds 50% equity. The board will also appoint Abhay Bhandari & Associates as Internal Auditor for FY 2026-27. Other items include fixing the EOGM cut-off date and remote e-voting period, appointing a scrutinizer, noting director interest disclosures, and giving tender-signing authority to Mr. Sudhir Sethi for FY 2026-27.

Likely market impact

The regularization of the WTD appointment and the material related party transaction with a director's own company (where he holds 50% equity) will require shareholder approval at the EOGM, which may draw governance attention. No negative financial or operational impact is indicated; most other items are routine annual approvals.